# GSK starts appeal process of recent Delaware Daubert decision

- Link: https://www.directorstalkinterviews.com/gsk-starts-appeal-process-of-recent-delaware-daubert-decision/4121159654
- Published: 2024-06-11T07:18:46+01:00
- Author: Amilia Stone

**[GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)**
has confirmed that the Company has taken the first step to seek appeal of the recent
Daubert ruling, made by the Delaware Superior Court, which permits plaintiff expert
testimony as part of the Zantac (ranitidine) litigation in Delaware. GSK strongly
disagrees with the Delaware Superior Court’s ruling and has filed an application
with the court to appeal to the Delaware Supreme Court for interlocutory review 
of the decision. Pfizer, Sanofi, and Boehringer Ingelheim are all parties to the
application.

·   Delaware Superior Court’s ruling inconsistent with how Daubert standard* has
previously been applied in Delaware and federal courts

·   Application has been filed seeking right of appeal to the Delaware Supreme Court

·   GSK, Pfizer, Sanofi, and Boehringer Ingelheim are all parties to the application

·   Scientific consensus remains that there is no consistent or reliable evidence
that ranitidine increases the risk of any cancer

While interlocutory reviews are granted in exceptional circumstances, GSK believes
such circumstances are present here and that it is important to raise these matters
now to the Delaware Supreme Court.

The Superior Court’s ruling is inconsistent with how the Daubert standard has been
applied previously in Delaware and federal courts. As such, differing rulings interpreting
how the Daubert standard is to be applied to litigation before Delaware Courts, 
now exist. The Superior Court’s ruling would therefore have profound implications
for all companies and businesses incorporated in Delaware.

If the Delaware Superior Court grants the application for appeal, the case for interlocutory
review of the decision will proceed to the Delaware Supreme Court for consideration.

If the Delaware Superior Court rejects the application, GSK and the other defendants
will seek leave to appeal directly to the Delaware Supreme Court.

A decision, on whether to grant interlocutory review and hear the appeal, would 
be expected from the Delaware Supreme Court sometime later this year.

The scientific consensus remains that there is no consistent or reliable evidence
that ranitidine increases the risk of any cancer. There are 16 epidemiological studies
looking at human data regarding the use of ranitidine, including outcomes for more
than 1 million patients using ranitidine, supporting this consensus.

GSK remains committed to vigorously defending itself and managing this litigation
in the best interests of the Company and its shareholders.

* Also known as the “Daubert Test,” the Daubert standard is a method used by US 
courts to determine whether or not expert testimony should be admissible at trial.
This standard applies to both civil and criminal cases and can be raised by either
the defendant or plaintiff. The standard came about because Federal Rule of Evidence
702 requires that expert testimony consists of scientific, technical or other specialised
knowledge that legitimately helps the judge or jury understand the evidence or issues
that have been raised in the case. A Daubert ruling, issued by the court, determines
whether or not the testimony is admissible.

Share on:
